Skip to main content

BioMarin Pharmaceutical Value Stock - Dividend - Research Selection

BioMarin Pharmaceutical

ISIN: US09061G1013, WKN: 924801

Market price date: 26.01.2022
Market price: 83,70 USD


BioMarin Pharmaceutical Fundamental data and company key figures of the share

Annual reports in USD
Key figures 01-03-2021
Cash flow
Net operating cash flow 85.365.000
Capital Expenditures -114.312.000
Free cash flow -28.947.000
Balance sheet
Total Equity 4.106.000.000
Liabilities & Shareholders equity 5.848.020.000
Income statement
Net income 859.100.000
Eps (diluted) 4,530
Diluted shares outstanding 181.000.000
Net sales/revenue 1.805.860.000

Fundamental ratios calculated on: 26-01-2022

Ratios
Key figures 26-01-2022
Cash flow
P/C 177,47
   
P/FC -523,36
Balance sheet
ROI14,69
ROE70,21
Income statement
P/E18,48
Div. Yield0,00%
P/B3,69
P/S8,39


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBMRN
Market Capitalization15.149.700.096,00 USD
CountryUnited States
IndicesNASDAQ 100,NASDAQ Comp.,MSCI World Index
SectorsBiotechnology
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.biomarin.com


Description of the company

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company's product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), and BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.biomarin.com


NEWS


Netflix shares fall near pre-pandemic level as investors fear slowing subscriber growth, competition

2022-01-24
Netflix tumbled for a second day on Monday after the company's weaker-than-expected subscriber forecast.

Stocks making the biggest moves midday: Netflix, Kohl's, Wynn Resorts, General Motors and more

2022-01-24
These are the stocks posting the largest moves in midday trading.

RBC upgrades Comcast to outperform on subscriber growth

2022-01-24
CNBC's Julia Boorstin reports on legal media companies which are ticking higher despite a broader sell-off. (Comcast is CNBC's parent company.)

BioMarin Pharmaceutical (BMRN) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

2022-01-24
The following slide deck was published by BioMarin Pharmaceutical Inc.

What to watch today: Wall Street to open lower after Nasdaq's worst week since March 2020

2022-01-24
U.S. stock futures indicated more losses to start the new week following the Nasdaq's and the S&P 500's worst weeks since March 2020.

Stocks making the biggest moves in the premarket: Kohl's, Snap, Peloton and more

2022-01-24
The stocks making the biggest moves in premarket trading include Kohl's, Snap, Peloton, and more.

Earnings playbook: A complete guide to this week's reports, including the first of tech

2022-01-23
Microsoft, Tesla and Apple will release quarterly results, alongside a handful of other tech firms. McDonald's and Boeing will also offer updates.

Markets are expected to remain on edge as the Fed meets in the week ahead

2022-01-21
The Federal Reserve's meeting trumps everything else for markets in the week ahead, as investors await any new clues on its plans to raise interest rates.

Netflix quietly admits streaming competition is eating into growth

2022-01-20
Netflix added a line in its quarterly shareholder letter acknowledging streaming competition is affecting its "marginal growth."

Lion Street Advisors, LLC Buys Compass Minerals International Inc, First Trust NASDAQ Rising ...

2022-01-20
Investment company Lion Street Advisors, LLC (Current Portfolio) buys Compass Minerals International Inc, First Trust NASDAQ Rising Dividend Achievers ETF, Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, Schwab Fundamental U.S.